Pulmonary MucormycosisRadioMucorNCT07339800
Chest CT Scan in Pulmonary Mucormycosis: Prognostic Value
An observational study of Pulmonary Mucormycosis, run by University Hospital, Strasbourg, France at 1 site in France.
Trial summary
Invasive pulmonary fungal infections caused by Mucorales are rare but severe and rapidly progressive, affecting immunocompromised patients. The role of chest imaging in their diagnosis is well established in the 2020 EORTC/MSGERC criteria, and its use is almost systematic. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pulmonary Mucormycosis
- How many people
- 80 participants
- Where
- 1 siteFrance
- Study dates
- 18 Sep 2025to 19 Sep 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patients with a diagnosis of probable or proven invasive pulmonary infection with Mucorales according to the 2020 EORTC/MSGERC criteria
Who may be able to join
- Patients aged 18 years or older
- Treated at Strasbourg University Hospital between January 1, 2009, and June 3, 2025
- With a diagnosis of probable or proven invasive pulmonary infection with Mucorales according to the 2020 EORTC/MSGERC criteria
- Having undergone at least one CT scan including the thoracic region
Who cannot join
- No CT scan including the thoracic region
- No diagnosis of probable or proven invasive pulmonary infection with Mucorales (EORTC/MSGERC 2020 criteria)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France
Strasbourg, 67091
Baptiste Hoellinger, MD, 33 3 69 55 05 45, baptiste.hoellinger@chru-strasbourg.fr
Baptiste Hoellinger, MD
About this study
Invasive pulmonary fungal infections caused by Mucorales are rare but severe and rapidly progressive, affecting immunocompromised patients. The role of chest imaging in their diagnosis is well established in the 2020 EORTC/MSGERC criteria, and its use is almost systematic. However, the progression of lung parenchymal involvement and any potential prognostic radiological patterns in the follow-up of these infections are less well understood. This research aims to identify imaging characteristics predictive of favorable or unfavorable outcomes in infected patients, in order to better tailor follow-up and therapeutic options.
- Conditions
- Pulmonary Mucormycosis
- Keywords
- Pulmonary Mucormycosis, Fungal infections
- Medical subject headings
- Mycoses
What is being measured
The primary outcome is the main question the study is designed to answer.
Death rate in patients with probable or proven invasive Mucorales infection
Death rate at day 15 in patients with probable or proven invasive Mucorales infection
Measured: Day 15 after infection
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jan 2026
- Study start18 Sep 2025
- Primary completionSep 2026 (estimated)
- Study completion19 Sep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pulmonary MucormycosisStudies of the same condition, open and under way.
- More trials run by University Hospital, Strasbourg, FranceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Strasbourg, France
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07339800
- Sponsor's protocol ID
- 9767
- Acronym
- RadioMucor
- Status last verified
- Jan 2026
- First submitted
- 5 Jan 2026
- Last updated
- 14 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Chest CT Scan in Pulmonary Mucormycosis: Prognostic Value
- ClinicalTrials.gov ID
- NCT07339800
- Acronym / sponsor ID
- RadioMucor / 9767
- Conditions
- Pulmonary Mucormycosis
- Keywords
- Pulmonary Mucormycosis, Fungal infections
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- University Hospital, Strasbourg, FranceUniversity, hospital or other
- Study start
- 18 Sep 2025 (actual)
- Primary completion
- Sep 2026 (estimated)
- Study completion
- 19 Sep 2026 (estimated)
- First posted
- 14 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Invasive pulmonary fungal infections caused by Mucorales are rare but severe and rapidly progressive, affecting immunocompromised patients. The role of chest imaging in their diagnosis is well established in the 2020 EORTC/MSGERC criteria, and its use is almost systematic. However, the progression of lung parenchymal involvement and any potential prognostic radiological patterns in the follow-up of these infections are less well understood. This research aims to identify imaging characteristics predictive of favorable or unfavorable outcomes in infected patients, in order to better tailor follow-up and therapeutic options.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients with a diagnosis of probable or proven invasive pulmonary infection with Mucorales according to the 2020 EORTC/MSGERC criteria
Key inclusion criteria (4 listed)
- Patients aged 18 years or older
- Treated at Strasbourg University Hospital between January 1, 2009, and June 3, 2025
- With a diagnosis of probable or proven invasive pulmonary infection with Mucorales according to the 2020 EORTC/MSGERC criteria
- Having undergone at least one CT scan including the thoracic region
Key exclusion criteria (2 listed)
- No CT scan including the thoracic region
- No diagnosis of probable or proven invasive pulmonary infection with Mucorales (EORTC/MSGERC 2020 criteria)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Death rate in patients with probable or proven invasive Mucorales infection
Time frame: Day 15 after infection
Death rate at day 15 in patients with probable or proven invasive Mucorales infection
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jan 2026.
Related trials for Pulmonary Mucormycosis
Not yet recruitingPhase 4
Antifungal Drugs in Pulmonary Mucormycosis
Pulmonary Mucormycosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pulmonary Mucormycosis, run by University Hospital, Strasbourg, France at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 14 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact baptiste Hoellinger, MD (33 3 69 55 05 45, baptiste.hoellinger@chru-strasbourg.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Death rate in patients with probable or proven invasive Mucorales infection (time frame: Day 15 after infection). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jan 2026.